Avrobio reports positive data from Phase I/II cystinosis gene therapy trial
The trial is assessing the safety and efficacy of AVR-RD-04 in adults with the infantile form of cystinosis.

The trial is assessing the safety and efficacy of AVR-RD-04 in adults with the infantile form of cystinosis.
On April 25, Nkarta, a biopharmaceutical company developing off-the-shelf engineered natural killer (NK) cell therapies, announced highly promising results from…
ByOn April 25, Axsome Therapeutics revealed that chemistry, manufacturing and controls (CMS) issues were identified during the US Food and…
ByGonorrhoea is the second most common nationally notifiable sexually transmitted infection (STI) in the US. It affects both men and…
ByMalaria is a vector-borne disease caused by parasites of the genus Plasmodium. Malaria is transmitted through the bite of the…
ByAs the Covid-19 pandemic stretches into its third year, the long-term effects of acute infection are beginning to become more…
ByMajor depressive disorder (MDD), also known as clinical depression or major depression, is widely recognised as a mood disorder that…
ByThe initial portion of the trial will assess increasing doses of the NK1R+ MSCs in adult patients.